Join
Live feed
·
PRReleasevia Quantisnow
Prometheus Biosciences Inc. logo

Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

ByQuantisnow·Wall Street's wire, on your screen.
RXDX· Prometheus Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RXDX (Prometheus Biosciences Inc.) and more on Quantisnow.